Marina N Nikiforova

List of Publications by Year in Descending Order

93 papers	12,729 citations	47 h-index	98 g-index
98 ext. papers	14,639 ext. citations	6 avg, IF	6.23 L-index

#	Paper	IF	Citations
93	Molecular profiling of papillary thyroid carcinomas in healthcare workers exposed to low dose radiation at the workplace.. *Endocrine*, **2022**, 76, 95	4	
92	Clinicopathologic Characteristics of Thyroid Nodules Positive for the Fusion on Preoperative Molecular Analysis. *Thyroid*, **2021**, 31, 1212-1218	6.2	4
91	Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size. *Gut*, **2021**,	19.2	15
90	Molecular alterations in H□thle cell nodules and preoperative cancer risk. *Endocrine-Related Cancer* , **2021**, 28, 301-309	5.7	6
89	Targeted next-generation sequencing supports serrated epithelial change as an early precursor to inflammatory bowel disease-associated colorectal neoplasia. *Human Pathology*, **2021**, 112, 9-19	3.7	0
88	Thyroid cytology smear slides: An untapped resource for ThyroSeq testing. *Cancer Cytopathology*, **2021**, 129, 33-42	3.9	9
87	Limitations of Detecting Genetic Variants from the RNA Sequencing Data in Tissue and Fine-Needle Aspiration Samples. *Thyroid*, **2021**, 31, 589-595	6.2	4
86	Prevalence and Spectrum of DICER1 Mutations in Adult-onset Thyroid Nodules with Indeterminate Cytology. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, 968-977	5.6	3
85	Risk assessment for distant metastasis in differentiated thyroid cancer using molecular profiling: A matched case-control study. *Cancer*, **2021**, 127, 1779-1787	6.4	3
84	Can TP53-mutant follicular adenoma be a precursor of anaplastic thyroid carcinoma?. *Endocrine-Related Cancer*, **2021**, 28, 621-630	5.7	2
83	KRAS amplification in metastatic colon cancer is associated with a history of inflammatory bowel disease and may confer resistance to anti-EGFR therapy. *Modern Pathology*, **2020**, 33, 1832-1843	9.8	8
82	Is Next-Generation Sequencing Alone Sufficient to Reliably Diagnose Gliomas?. *Journal of Neuropathology and Experimental Neurology*, **2020**, 79, 763-766	3.1	3
81	Recurrent Rearrangements in PRKACA and PRKACB in Intraductal Oncocytic Papillary Neoplasms of the Pancreas and□Bile Duct. *Gastroenterology*, **2020**, 158, 573-582.e2	13.3	56
80	The histopathology of SPINK1-associated chronic pancreatitis. *Pancreatology*, **2020**, 20, 1648-1655	3.8	4
79	Integrating next-generation sequencing to endoscopic retrograde cholangiopancreatography (ERCP)-obtained biliary specimens improves the detection and management of patients with malignant bile duct strictures. *Gut*, **2020**, 69, 52-61	19.2	48
78	Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens. *Cancer Cytopathology*, **2019**, 127, 285-296	3.9	24
77	Targeted mutation detection in breast cancer using MammaSeq□*Breast Cancer Research*, **2019**, 21, 22	8.3	22

76	Spectrum of TERT promoter mutations and mechanisms of activation in thyroid cancer. *Cancer Medicine*, **2019**, 8, 5831-5839	4.8	26
75	Characterization of Activating Mutations of the Gene in Papillary Thyroid Carcinomas. *Thyroid*, **2019**, 29, 1279-1285	6.2	5
74	Interactive Browser-Based Genomics Data Visualization Tools for Translational and Clinical Laboratory Applications. *Journal of Molecular Diagnostics*, **2019**, 21, 985-993	5.1	4
73	GLIS rearrangements in thyroid nodules: A key to preoperative diagnosis of hyalinizing trabecular tumor. *Cancer Cytopathology*, **2019**, 127, 560-566	3.9	7
72	MiRNAs Are Involved in Tall Cell Morphology in Papillary Thyroid Carcinoma. *Cancers*, **2019**, 11,	6.6	7
71	Characterization of thyroid cancer driven by known and novel ALK fusions. *Endocrine-Related Cancer*, **2019**, 26, 803-814	5.7	19
70	Benign call rate and molecular test result distribution of ThyroSeq v3. *Cancer Cytopathology*, **2019**, 127, 161-168	3.9	24
69	Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study. *JAMA Oncology*, **2019**, 5, 204-212	13.4	171
68	GLIS Rearrangement is a Genomic Hallmark of Hyalinizing Trabecular Tumor of the Thyroid Gland. *Thyroid*, **2019**, 29, 161-173	6.2	34
67	Incidental Diagnosis of Parathyroid Lesions by Preoperative Use of Next-Generation Molecular Testing. *World Journal of Surgery*, **2018**, 42, 2840-2845	3.3	1
66	Loss of Chromatin-Remodeling Proteins and/or CDKN2A Associates With Metastasis of Pancreatic Neuroendocrine Tumors and Reduced Patient Survival Times. *Gastroenterology*, **2018**, 154, 2060-2063.e8	13.3	41
65	Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules. *Cancer*, **2018**, 124, 1682-1690	6.4	180
64	AuthorsSReply. *Journal of Molecular Diagnostics*, **2018**, 20, 125-126	5.1	0
63	Investigation of the Relationship Between Radiation Dose and Gene Mutations and Fusions in Post-Chernobyl Thyroid Cancer. *Journal of the National Cancer Institute*, **2018**, 110, 371-378	9.7	32
62	Cancer risk and clinicopathological characteristics of thyroid nodules harboring thyroid-stimulating hormone receptor gene mutations. *Diagnostic Cytopathology*, **2018**, 46, 369-377	1.4	14
61	Clinical Implementation and Validation of Automated Human Genome Variation Society (HGVS) Nomenclature System for Next-Generation Sequencing-Based Assays for Cancer. *Journal of Molecular Diagnostics*, **2018**, 20, 628-634	5.1	5
60	DNA testing of pancreatic cyst fluid: is it ready for prime time?. *The Lancet Gastroenterology and Hepatology*, **2017**, 2, 63-72	18.8	14
59	fusion is a mechanism of IGF2BP3 activation and IGF1R signaling in thyroid cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 2307-2312	11.5	34

58	Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma. *Modern Pathology*, **2017**, 30, 1133-1143	9.8	28
57	Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists. *Journal of Molecular Diagnostics*, **2017**, 19, 341-365	5.1	310
56	Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. *Journal of Molecular Diagnostics*, **2017**, 19, 4-23	5.1	744
55	Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens. *Cancer Cytopathology*, **2017**, 125, 615-626	3.9	43
54	Preoperative detection of RAS mutation may guide extent of thyroidectomy. *Surgery*, **2017**, 161, 168-175	3.6	39
53	Identification of Targetable Rearrangements in Pancreatic Ductal Adenocarcinoma. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2017**, 15, 555-562	7.3	46
52	Molecular Characterization of Sporadic Pediatric Thyroid Carcinoma with the DNA/RNA ThyroSeq v2 Next-Generation Sequencing Assay. *Pediatric and Developmental Pathology*, **2016**, 19, 115-22	2.2	51
51	Response of relapsed central nervous system hairy cell leukemia to vemurafenib. *Leukemia and Lymphoma*, **2016**, 57, 2952-2954	1.9	3
50	Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors. *Neuro-Oncology*, **2016**, 18, 379-87	1	75
49	A Multiplexed Amplicon Approach for Detecting Gene Fusions by Next-Generation Sequencing. *Journal of Molecular Diagnostics*, **2016**, 18, 165-75	5.1	57
48	Targeted Next-Generation Sequencing Analysis of a Pendred Syndrome-Associated Thyroid Carcinoma. *Endocrine Pathology*, **2016**, 27, 70-5	4.2	12
47	American Gastroenterological Association guidelines are inaccurate in detecting pancreatic cysts with advanced neoplasia: a clinicopathologic study of 225 patients with supporting molecular data. *Gastrointestinal Endoscopy*, **2016**, 83, 1107-1117.e2	5.2	116
46	Histopathologic and Clinical Characterization of Thyroid Tumors Carrying the BRAF(K601E) Mutation. *Thyroid*, **2016**, 26, 242-7	6.2	65
45	Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients. *Clinical Cancer Research*, **2016**, 22, 1130-7	12.9	144
44	ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma. *Oncotarget*, **2016**, 7, 82943-82952	3.3	49
43	NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States. *Cancer*, **2016**, 122, 1097-107	6.4	147
42	Colorectal poorly differentiated neuroendocrine carcinomas frequently exhibit BRAF mutations and are associated with poor overall survival. *Human Pathology*, **2016**, 49, 124-34	3.7	36
41	Next-Generation Sequencing Informatics: Challenges and Strategies for Implementation in a Clinical Environment. *Archives of Pathology and Laboratory Medicine*, **2016**, 140, 958-75	5	54

40	Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. *JAMA Oncology*, **2016**, 2, 1023-9	13.4	895
39	The clinical importance of parathyroid atypia: is long-term surveillance necessary?. *Surgery*, **2015**, 158, 929-35; discussion 935-6	3.6	23
38	Mutations of TSHR and TP53 Genes in an Aggressive Clear Cell Follicular Carcinoma of the Thyroid. *Endocrine Pathology*, **2015**, 26, 315-9	4.2	13
37	Clinicopathological comparison of colorectal and endometrial carcinomas in patients with Lynch-like syndrome versus patients with Lynch syndrome. *Human Pathology*, **2015**, 46, 1616-25	3.7	48
36	Molecular characterization of apocrine salivary duct carcinoma. *American Journal of Surgical Pathology*, **2015**, 39, 744-52	6.7	78
35	Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology. *Thyroid*, **2015**, 25, 1217-23	6.2	282
34	SeqReporter: automating next-generation sequencing result interpretation and reporting workflow in a clinical laboratory. *Journal of Molecular Diagnostics*, **2014**, 16, 11-22	5.1	26
33	Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. *Cancer*, **2014**, 120, 3627-34	6.4	379
32	Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 4233-8	11.5	191
31	MicroRNA profile of poorly differentiated thyroid carcinomas: new diagnostic and prognostic insights. *Journal of Molecular Endocrinology*, **2014**, 52, 181-9	4.5	70
30	Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma. *Neuro-Oncology*, **2014**, 16, 1478-83	1	51
29	Serrated lesions of the appendix frequently harbor KRAS mutations and not BRAF mutations indicating a distinctly different serrated neoplastic pathway in the appendix. *Human Pathology*, **2014**, 45, 227-35	3.7	43
28	Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, E1852-60	5.6	344
27	MicroRNA expression array identifies novel diagnostic markers for conventional and oncocytic follicular thyroid carcinomas. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, E1-7	5.6	85
26	Comprehensive MicroRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma. *Thyroid*, **2013**, 23, 1383-9	6.2	103
25	LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma. *Clinical Cancer Research*, **2013**, 19, 1816-26	12.9	57
24	Molecular genetics and diagnosis of thyroid cancer. *Nature Reviews Endocrinology*, **2011**, 7, 569-80	15.2	632
23	MicroRNA dysregulation in human thyroid cells following exposure to ionizing radiation. *Thyroid*, **2011**, 21, 261-6	6.2	33

22	MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. *Annals of Surgical Oncology*, **2011**, 18, 2035-41	3.1	192
21	Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, 3390-7	5.6	614
20	Molecular diagnostics of gliomas. *Archives of Pathology and Laboratory Medicine*, **2011**, 135, 558-68	5	55
19	miRNA expression profiling of lung adenocarcinomas: correlation with mutational status. *Modern Pathology*, **2010**, 23, 1577-82	9.8	119
18	Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. *Journal of Clinical Endocrinology and Metabolism*, **2009**, 94, 2092-8	5.6	590
17	Molecular diagnostics and predictors in thyroid cancer. *Thyroid*, **2009**, 19, 1351-61	6.2	258
16	Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. *Surgery*, **2009**, 146, 1215-23	3.6	138
15	MicroRNA expression profiles in thyroid tumors. *Endocrine Pathology*, **2009**, 20, 85-91	4.2	96
14	Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. *Expert Review of Molecular Diagnostics*, **2008**, 8, 83-95	3.8	227
13	MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. *Journal of Clinical Endocrinology and Metabolism*, **2008**, 93, 1600-8	5.6	485
12	Detection of clonal IGH gene rearrangements: summary of molecular oncology surveys of the College of American Pathologists. *Archives of Pathology and Laboratory Medicine*, **2007**, 131, 185-9	5	14
11	Examination of Chromosome 1p Alterations in Glioblastomas. *FASEB Journal*, **2007**, 21, A393	0.9	
10	Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 3603-10	5.6	174
9	Detection of SYT-SSX rearrangements in synovial sarcomas by real-time one-step RT-PCR. *Pediatric and Developmental Pathology*, **2005**, 8, 162-7	2.2	6
8	Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. *Journal of Clinical Investigation*, **2005**, 115, 94-101	15.9	307
7	Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. *Cancer Letters*, **2004**, 209, 1-6	9.9	131
6	Molecular Profile and Clinical-Pathologic Features of the Follicular Variant of Papillary Thyroid Carcinoma. *American Journal of Clinical Pathology*, **2003**, 120, 71-77	1.9	338
5	BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 5399-404	5.6	836

4	RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 2318-26	5.6	557
3	High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. *Cancer Research*, **2003**, 63, 1454-7	10.1	977
2	PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. *American Journal of Surgical Pathology*, **2002**, 26, 1016-23	6.7	298
1	Prevalence of RET/PTC rearrangements in Hashimoto's thyroiditis and papillary thyroid carcinomas. *International Journal of Surgical Pathology*, **2002**, 10, 15-22	1.2	114